The American Hospital Association expresses concern about Eli Lilly’s January 2026 claims-data policy and invites Lilly to work in good faith with the AHA and our 340B hospital members to find a ...
Despite dramatic expansion over the past 34 years, many rural and underserved hospitals continue to face significant financial pressures and closures, underscoring concerns about whether 340B is ...
On October 26, 2023, the Health Resources and Services Administration (HRSA) issued a Notice to “inform and remind” 340B Program covered entities that to be considered eligible for the 340B program, ...
Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...
The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...
The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.
One of the critical components for Mainers as they navigate the medical quagmire of insurance, providers and treatment is obtaining effective and safe drugs. Cancer treatment is often a long, taxing ...
The 340B drug plan language that was recently added into Senate Bill 494 risks increasing costs for the very patients it purports to help.
Pillr Health, a leading provider of software and tech-enabled services that optimize pharmacy operations, today announced it ...
Just days and weeks away from key deadlines, the hospital industry’s leading trade organization is still calling for the administration to scrap a one-year pilot of drugmakers’ preferred approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results